Securities code: 002435 securities abbreviation: Changjiangrunfa Health Industry Co.Ltd(002435) Announcement No.: 2022-006 Changjiangrunfa Health Industry Co.Ltd(002435)
2021 annual performance forecast
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and there are no false records, misleading statements or major omissions.
1、 Expected performance of the current period
1. Performance forecast period: January 1, 2021 to December 31, 2021
2. Expected operating performance: √ loss \uf0f0 turning loss into profit \uf0f0 rising in the same direction \uf0f0 falling in the same direction
The current reporting period of the project is the same period of last year
Loss attributable to listed companies: 350 million yuan – 45 million yuan; Profit: 247.6903 million yuan
Net profit of shareholders
Deducting non recurring losses: 520 million yuan – 620 million yuan; Profit: 151.9567 million yuan
Net profit after profit
Basic earnings per share loss: 0.2832 yuan / share – 0.3641 yuan / share earnings: 0.2004 yuan / share
Operating income: 400 million yuan – 450 million yuan 4240.5842 million yuan
After deduction, the operating income is 400 million yuan – 450 million yuan, 42289624 million yuan
Note: 1. Operating income after deduction refers to the operating income after deducting the business income irrelevant to the main business and the income without commercial substance.
2. There is a difference between the same period of last year and the data in the 2020 annual report disclosed by the company in the previous period. For details, see the suggestive announcement on correction and retroactive adjustment of accounting errors in the previous period (Announcement No.: 2021-070) disclosed by the company on December 30, 2021. The company’s annual audit accounting firm has issued a special audit report on this.
2、 Communication with accounting firms
The relevant data of this performance forecast is the preliminary calculation result of the company’s financial department and has not been audited by an accounting firm. The company has made pre communication with the annual audit accounting firm on major matters related to the performance forecast, and there is no significant difference between the company and the accounting firm in the performance forecast in the reporting period.
3、 Explanation of performance change reasons
During the reporting period, the main reasons for the change of the company’s operating performance compared with the same period of last year are as follows:
1. With the continuous promotion and deepening of the reform of the medical and health system, the state continues to strengthen the control of drug prices, especially volume procurement, national centralized procurement, price linkage and price negotiation, which has a great impact on the whole pharmaceutical industry. In the fourth quarter of 2021, ceftazidime for injection, the main product of the company’s Hainan Hailing Chemical Pharmaceutical Co., Ltd., began to implement the fifth batch of national centralized drug procurement, and the profitability of the company’s pharmaceutical business segment was lower than the previous forecast. Based on the principle of prudence, combined with the actual business situation and changes in industrial policies and other factors, and in accordance with the accounting standards for Business Enterprises No. 8 – asset impairment and relevant accounting policies, the company has preliminarily evaluated and calculated the goodwill assets, and plans to withdraw the provision for goodwill impairment of 650 million yuan to 75 million yuan, The final amount of goodwill impairment will be determined after evaluation and audit by professional evaluation institutions and audit institutions hired by the company. During the reporting period, after deducting the impact of goodwill impairment, the company’s operating performance achieved stable development compared with the same period of last year. 2. During the reporting period, the company expects the impact of non recurring profits and losses on the company’s net profit to be about 170 million yuan, mainly including 134 million yuan of performance commitment compensation and government subsidies included in the current income. The final result is subject to the audit confirmation of the annual report audit accounting firm.
4、 Risk tips
This performance forecast is the preliminary accounting conducted by the financial department of the company based on the annual operation and its own professional judgment, which has not been audited by certified public accountants. The company has no major uncertainties affecting the accuracy of the performance forecast.
5、 Other relevant instructions
The above forecast data are only preliminary accounting data, and the specific financial data will be disclosed in detail in the company’s 2021 annual report. Please make careful decisions and pay attention to investment risks.
It is hereby announced.
Changjiangrunfa Health Industry Co.Ltd(002435) board of directors January 29, 2022
